The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Effect Of Non-Invasive Vagus Nerve Stimulation In Freezing And Oxidative Stress In Parkinson’s Disease Patients
Objective: In this observational pilot study we explored the long term effect of Non-Invasive VNS to improve the FOG and reduce oxidative stress in PD…Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials
Objective: To identify and overcome challenges to recruiting minorities in Parkinson's Disease experimental therapeutic trials. Background: Inadequate representation of ethnic and minority population poses substantial…ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…Differences in cerebral perfusion between Major depression disorder and depression with Parkinson’s disease : Brain HMPAO SPECT study using SPM analysis
Objective: We performed SPECT in Major depressive (MD) disorder and PD patients with (PDMD) and without depression (PDNMD). The aim of this work was to…Clinical Utility of Optimized Parameters for a Quantitative Analysis of 123I-ioflupane SPECT (DaTscan) Images
Objective: Validate an automated analysis of DaTscan SPECT images on a representative cohort of patients for discriminating between Parkinson's Disease (PD) versus non-PD. Background: Quantitation…Cortical phase-amplitude coupling across Parkinson’s disease phenotypes measured with magnetoencephalograph
Objective: To investigate how onset mode in Parkinson’s disease relates to cortical phase-amplitude coupling, a putative electrophysiological marker of pathological hypersynchronization. Background: Cortical circuitry in…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 155
- Next Page »